- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 15,613
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- accelerated hypofractionated radiotherapy (AHF-RT)
- Radiation
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Tumor, Cancer, Melanoma, Sarcoma, Carcinoma
- Interventions
- Hypofractionated RT
- Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Eosinophilia, Angioedema
- Interventions
- mepolizumab
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Localized Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Metastatic Breast Cancer
- Interventions
- Best Practice, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet
- Drug · Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Burn Scar
- Interventions
- silicone spray, saline spray
- Other
- Lead sponsor
- United States Army Institute of Surgical Research
- Federal
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer
- Interventions
- Kidney Function Test
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hair Thinning, Facial Skin Texture, Skin Ageing
- Interventions
- Biotin and silicon, Placebo
- Dietary Supplement
- Lead sponsor
- Nutrition 21, Inc.
- Industry
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Breast Cancer
- Interventions
- ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Inflammation, Cancer, Pain, Hypertension
- Interventions
- Sulindac
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- Up to 75 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Stony Brook, New York
- Conditions
- Breast Cancer
- Interventions
- Peace of Mind Program
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 4,448 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Psoriasis
- Interventions
- PRX003, Placebo
- Drug · Other
- Lead sponsor
- Prothena Biosciences Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 9
- States / cities
- San Diego, California • Coral Gables, Florida • Ocala, Florida + 6 more
- Conditions
- Metastatic Breast Cancer, Unresectable Breast Cancer
- Interventions
- DiviTum® TKa assay
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer
- Interventions
- Arm 1 Daily Boost of Radiation Therapy, Arm 2 Weekly Boost of Radiation Therapy
- Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Neoplasms
- Interventions
- Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- DYP688
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Interventions
- Exemestane, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 75 Years · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Tampa, Florida • New York, New York • Houston, Texas
- Conditions
- Keloid, Keloid Scar Following Surgery
- Interventions
- Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
- Drug
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Psoriasis, Plaque-type
- Interventions
- Thalidomide oral
- Drug
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
- Interventions
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Other · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Fremont, California